Navigation Links
Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance
Date:8/7/2009

dness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2008, as amended; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
4. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
5. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference
6. Warner Chilcott Announces 2008 Financial Guidance
7. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
10. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
11. Warner Chilcott Announces Settlement of Securities Litigation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009),, NEWYORK,Nov.23/PRNewswire/--Livingwithchronicpaincanbedifficult-andthestressoftheholidayseasoncanprovetobequitechallengingforthoselivingwithpain. ,, ListentothisreportfromPfizerInc.at: ,
(Date:11/23/2009)...ter suffering from women,s hair loss for almost te...d she,s sharing her progress and the secret behind... the release of her video diaries which include a ...r treatment. , (PRWeb UK)...er Zsanett Siklosi has released the video diaries ...
(Date:11/23/2009)...RNewswire-FirstCall/--InfoLogix,Inc.(Nasdaq: IFLG ...lutionsforthehealthcareandcommercialindustries,ann...ServicesatSiemensHealthServices,hasjoinedInfoLogix..., (Logo: http://www.newscom.com/cgi-bin/prnh/20090...HealthcareServicesforInfoLogix,Mr.Waywillberespons...
(Date:11/23/2009)...atients and survivors treated with chemotherapy su... chronic conditions, hindering patients, ability t...iversity of Rochester Medical Center. , A study ...ep troubles at nearly three times the rate of the ... in younger patients and those with lung and breas...
(Date:11/23/2009)...rop by 63 percent with moderate-to-high intensity ...News) -- Moderate-to-high intensity exercise such ...oke risk in older men but not in women, researcher... and women, average age 69, in Manhattan who were ...here were 238 strokes among the participants. At t...
Breaking Medicine News(10 mins):Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2
...ts have provided new details about how proteins us...Alzheimer's disease. Gunnar K. Gouras, as... Weill Medical College of Cornell University, New ... for a vaccine against the disease. "Antib...
...alf the central government funds allocated to figh...n southern states that, ironically, were strugglin...ected at least 1.4 million people across the count... help them contain the chikungunya fever. But a su...
...ll establish 30 world-class universities across th...country's entry into the knowledge economy, Prime... "This expansion is going to be a landmark in ...mong the top institutions in the world," the prime...
...must provide more flexible working, the BMA says t... that female doctors embarking on NHS careers outn...t of 435 doctors who graduated from UK medical sch...ed a similar study of medical graduates. This is i...
... with radiation retinopathy who were destined to g... longer through localized treatment with Avastin ,... study published in the June, 2007 Archives of Oph...thy, said Paul T. Finger, MD, lead author of the s...
...iction worldwide appears to be slowing down for al...s Office on Drugs and Crime said on Friday. "...uth of Afghanistan, a cancer that threatens secur.... "Furthermore, progress made in some countrie...
Other Medicine News:Health News:Researchers Link Bacteria Destroying Proteins to Alzheimer's Treatment 2Health News:Researchers Link Bacteria Destroying Proteins to Alzheimer's Treatment 3Health News:Chikungunya Spreads as Funds Remain Unspent 2Health News:India to Have 30 World-class Universities Across the Country: PM 2Health News:BMA Calls for Flexible Working as Number of Women Doctors Swell 2Health News:Untreatable Eye Disease Improves With Avastin 2Health News:Drug Addiction Slowing Down: UN Report 2
(Date:11/23/2009)...3/PRNewswire/--TwooftheChicagoarea,sleadingBoardCe...inwomen,sbreastimaging,couplingthelatesttechnology...soundwiththeabilitytohavethefullrangeofdigitalimag...foresheleavestheoffice.Drs.AhmedFaragandJoanWerber...hecurrent6-9monthwaitforanappointmentcommonlyfound...
(Date:11/23/2009)...23/PRNewswire-FirstCall/--NuVasive, Inc. (Nasdaq: ...ductsforminimallydisruptivesurgicaltreatmentsforth...hiefExecutiveOfficer,andMichaelJ.Lambert,Executive...topresentatthe21stAnnualPiperJaffrayHealthCareConf...day,December2,2009,at10:00a.m.ET.Mr.LukianovandMr....
(Date:11/23/2009)...Nov.23/PRNewswire-FirstCall/--Immucor,Inc.(Nasdaq:...t-reagentsystemstothebloodtransfusionindustry,toda...fray21stAnnualHealthCareConferenceinNewYork,NYwill...Company,spresentationisscheduledforTuesday,Decembe...tionwillbeavailablethroughthe"AboutUs--InvestorInf...
Breaking Medicine Technology:NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 2NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 32009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60 25 Despite Current Recession 12440 12009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60 25 Despite Current Recession 12440 2Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 4527 1Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 4527 2Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 4527 3Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 4527 4Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 4527 5Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials 4527 6Global Decompression Announces C O D Available on All Used Axiom DRX 9000 Spinal Decompression Systems 47748 1Global Decompression Announces C O D Available on All Used Axiom DRX 9000 Spinal Decompression Systems 47748 2
... Program for Oral Compounds,to Treat Alcohol Depe...2, 2007--Alkermes, Inc.,(Nasdaq: ALKS) today annou...trial of ALKS 29 in alcohol dependent patients. Ba...rward with its,development program for oral produc...is a combination of two agents with distinct,pharm...
...07 -- DOR BioPharma, Inc.,(OTCBB: DORB) ("DOR" or ...lts from testing of a multivalent form of its botu...lished in the journal,Infection and Immunity (Ravi...75, p. 3043 ). These results are the first that,de...valent vaccine,that is active by the mucosal route...
Other Medicine Technology:Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 2Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 3Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 4DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 6
Chemstrip Micral
QED A350 Saliva Alcohol Test
AccuSign DOA Series Tests
...highly accurate in detecting the presence of drugs... GC/MS testing. This assay provides a preliminary ...uch as GC/MS) must be used in order to obtain a co...plied to any drug of abuse test result, particular...
Medicine Products: